Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - lopinavir, quantity: 100 mg; ritonavir, quantity: 25 mg - tablet, film coated - excipient ingredients: titanium dioxide; polyvinyl alcohol; macrogol 3350; purified talc; colloidal anhydrous silica; iron oxide yellow; copovidone; sorbitan monolaurate; sodium stearylfumarate - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older. this indication is based on the analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled clinical studies (see clinical trials).

Awstralja - Ingliż - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - lopinavir, quantity: 200 mg; ritonavir, quantity: 50 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; macrogol 3350; hyprolose; macrogol 400; colloidal anhydrous silica; polysorbate 80; purified talc; copovidone; titanium dioxide; iron oxide yellow; hypromellose; sorbitan monolaurate - kaletra is indicated for the treatment of hiv-1 infection, in combination with other antiretroviral agents in adults and children aged 2 years and older. this indication is based on the analyses of plasma hiv-1 rna levels and cd4 cell counts from controlled clinical studies (see clinical trials).

Kenja - Ingliż - Pharmacy and Poisons Board

cipla house, peninsula business park, ganpatrao… cipla house, peninsula business park, ganpatrao - lopinavir & ritonavir - tablet - lopinavir 200mg & ritonavir 50mg - lopinavir and ritonavir

Unjoni Ewropea - Ingliż - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - hiv infections - antivirals for systemic use - ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv 1 infected patients (adults and children of 2 years of age and older).

Kenja - Ingliż - Pharmacy and Poisons Board

lopinavir and ritonavir - film-coated tablet - lopinavir 100mg and ritonavir 25 mg tablets - ritonavir

Stati Uniti - Ingliż - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir tablets are indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection in adults and pediatric patients 14 days and older. limitations of use:  • genotypic or phenotypic testing and/or treatment history should guide the use of lopinavir and ritonavir tablets. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir tablets [see microbiology (12.4)]. • lopinavir and ritonavir tablets are contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. • lopinavir and ritonavir tablets are contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious an

Stati Uniti - Ingliż - NLM (National Library of Medicine)

laurus labs limited - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see drug interactions (7.1) and clinical pharmacology (12.3)] .          

Stati Uniti - Ingliż - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir and ritonavir is indicated in combination with other antiretroviral agents for the treatment of hiv- 1 infection in adults and pediatric patients 14 days and older. limitations of use: - genotypic or phenotypic testing and/or treatment history should guide the use of  lopinavir and ritonavir. the number of baseline lopinavir resistance-associated substitutions affects the virologic response to lopinavir and ritonavir [ see microbiology (12.4)] . - lopinavir and ritonavir is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., toxic epidermal necrolysis, stevens-johnson syndrome, erythema multiforme, urticaria, angioedema) to any of its ingredients, including ritonavir. - lopinavir and ritonavir is contraindicated with drugs that are highly dependent on cyp3a for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening reactions [see 

Kenja - Ingliż - Pharmacy and Poisons Board

cipla ltd cipla house, peninsula business park, ganpatrao - lopinavir & ritonavir oral pellets 40 mg /10 mg - tablet - 40 mg lopinavir and 10 mg ritonavir per capsule - lopinavir and ritonavir

Stati Uniti - Ingliż - NLM (National Library of Medicine)

doh central pharmacy - lopinavir (unii: 2494g1jf75) (lopinavir - unii:2494g1jf75), ritonavir (unii: o3j8g9o825) (ritonavir - unii:o3j8g9o825) - lopinavir 200 mg - kaletra is indicated in combination with other antiretroviral agents for the treatment of hiv-1 infection. the following points should be considered when initiating therapy with kaletra: - the use of other active agents with kaletra is associated with a greater likelihood of treatment response [see clinical pharmacology (12.4) and clinical studies (14)] . - genotypic or phenotypic testing and/or treatment history should guide the use of kaletra [see clinical pharmacology (12.4)] . the number of baseline primary protease inhibitor mutations affects the virologic response to kaletra [see clinical pharmacology (12.4)] . - once daily administration of kaletra is not recommended for therapy-experienced adult patients or any pediatric patients. ● kaletra is contraindicated in patients with previously demonstrated clinically significant hypersensitivity (e.g., stevens-johnson syndrome, erythema multiforme) to any of its ingredients, including ritonavir. ●  co-administration of kaletra is contraindicated with drugs t